Posts by Peptra Labs Research
BPC-157 Grown in Bacteria: 82.9% Ulcer Inhibition in Rats
BPC-157 was expressed as a fusion protein in Bacillus licheniformis and cut ethanol ulcers in rats by up to 82.9%, the authors report.
Semaglutide ESSENCE Subgroup: Why 116 Patients Is Too Few
Semaglutide resolved steatohepatitis in 63.1% of 116 Japanese ESSENCE participants. The fibrosis endpoint could not separate at that sample size.
Tirzepatide CV Approval: The Overlooked 0.92 Hazard Ratio
Tirzepatide gained an FDA cardiovascular indication on 28 August 2026, from a trial that met non-inferiority and missed superiority at P = 0.09.
Semaglutide and NAION: 2.33 Relative, 0.16 Points Absolute
Semaglutide initiators had 2.33 times the NAION risk of SGLT2 users in 102,361 veterans. The absolute difference was 0.16 percentage points.
Semaglutide vs Surgery: Same Stiffness Drop, Less Fat Loss
Semaglutide cut liver fat about half as much as sleeve gastrectomy over 72 weeks, and liver stiffness fell by the same relative amount.
GLP-1 in Serious Mental Illness: 764,115 Matched Pairs
GLP-1 initiation was linked to lower four-year mortality than SGLT2 inhibitors in serious mental illness, and the absolute gap was larger there.
GLP-1 Below BMI 27: Benefit With Little Weight to Lose
GLP-1 receptor agonists cut coded heart failure in type 2 diabetes with a BMI under 27, where there is almost no weight left to lose.
MOTS-c and Exercise: 9 Studies Out of 435 Records Screened
MOTS-c levels tend to rise after exercise, says a 2026 systematic review. Nine studies survived screening out of 435, and the authors say so.
Semaglutide vs Tirzepatide in FAERS: 192,791 US Reports
Semaglutide carried the cardiac reporting signals in a 2026 FAERS analysis, despite tirzepatide having more than twice as many reports overall.
MOTS-c in Sepsis Cardiomyopathy: Plausible, Not Validated
MOTS-c touches every process that goes wrong in septic hearts. A 2026 review separates the direct evidence from what was borrowed elsewhere.